Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15007534 | 0.79 | TSHR (0.50) | TSHRNPSR1RXFP1HDAC3HDAC4 | |
| SCHEMBL736439 | 0.78 | TSHR (0.61) | TSHRNPSR1RXFP1HDAC3HDAC4 | |
| SCHEMBL29389351 | 0.78 | TSHR (0.61) | TSHRNPSR1RXFP1HDAC3HDAC4 | |
| SCHEMBL17110689 | 0.76 | TSHR (0.59) | TSHRNPSR1RXFP1HDAC3HDAC4 | |
| SCHEMBL31483487 | 0.76 | TSHR (0.59) | TSHRNPSR1RXFP1HDAC3HDAC4 | |
| SCHEMBL640172 | 0.76 | TSHR (0.54) | TSHRNPSR1RXFP1HDAC3HDAC4 | |
| SCHEMBL8404027 | 0.75 | TSHR (0.58) | TSHRNPSR1RXFP1HDAC3HDAC4 | |
| SCHEMBL798347 | 0.75 | TSHR (0.58) | TSHRNPSR1RXFP1HDAC3HDAC4 | |
| SCHEMBL21104745 | 0.75 | TSHR (0.58) | TSHRNPSR1RXFP1HDAC3HDAC4 | |
| SCHEMBL2751 | 0.75 | TSHR (0.58) | TSHRNPSR1RXFP1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115023431-B | Triterpene compounds, pharmaceutical compositions thereof and use thereof in the treatment of diseases mediated by member 1 of the nuclear receptor subfamily 4 | 藤济(厦门)生物医药科技有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-115023431-A | Triterpenoids, pharmaceutical compositions thereof and use thereof in the treatment of diseases mediated by group 4 members of the nuclear receptor subfamily | 藤济(厦门)生物医药科技有限公司 | 2022-09-06 | — | — | CN | claimed |
| EP-1700922-B1 | 3-Substituted 5-Nitroindole derivatives and labeled oligonucleotide probes containing them | ROCHE DIAGNOSTICS GMBH (DE) | 2016-08-24 | — | — | EP | claimed |
| US-7772357-B2 | Hydrolytically degradable polymers and hydrogels made therefrom | NEKTAR THERAPEUTICS (US) | 2010-08-10 | — | — | US | claimed |
| US-7695980-B2 | Chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-04-13 | — | — | US | claimed |
| US-20100004392-A1 | Hydrolytically Degradable Polymers and Hydrogels Made Therefrom | NEKTAR THERAPEUTICS (US) | 2010-01-07 | — | — | US | claimed |
| EP-1646609-B1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2009-10-14 | — | — | EP | claimed |
| US-7563902-B2 | Chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2009-07-21 | — | — | US | claimed |
| EP-1476489-B8 | HYDROLYTICALLY DEGRADABLE ALKYLENE OXIDE BASED POLYMERS | NEKTAR THERAPEUTICS AL CORP (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1476489-B1 | HYDROLYTICALLY DEGRADABLE ALKYLENE OXIDE BASED POLYMERS | NEKTAR THERAPEUTICS AL CORP (US) | 2008-04-09 | — | — | EP | claimed |
| US-20060199833-A1 | Novel chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-09-07 | — | — | US | claimed |
| US-20060199223-A1 | storage stability; immunoassays | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-09-07 | — | — | US | claimed |
| US-20060172358-A1 | Novel chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-08-03 | — | — | US | claimed |
| EP-1476489-A1 | HYDROLYTICALLY DEGRADABLE ALKYLENE OXIDE BASED POLYMERS | Nektar Therapeutics Al, Corporation (US) | 2004-11-17 | — | — | EP | claimed |
| WO-2003070805-A1 | HYDROLYTICALLY DEGRADABLE ALKYLENE OXIDE BASED POLYMERS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2003-08-28 | — | — | WO | claimed |
| US-20030023023-A1 | Hydrolytically degradable polymers and hydrogels made therefrom | SHEARWATER CORPORATION | 2003-01-30 | — | — | US | claimed |
| US-6348558-B1 | OLIGOMERS COMPRISING ALKYLENE OXIDE MONOMERS AND CARBONATE LINKAGES; POLYCARBONATEETHER COPOLYMERS; DRUG DELIVERY; CONJUGATED TO PEPTIDES OR PROTEINS FOR REDUCED IMMUNOGENICITY; STABILITY | SHEARWATER CORPORATION | 2002-02-19 | — | — | US | claimed |
| US-5532171-A | PHENOTHIAZINE DYES FOR PHOTODYNAMIC THERAPY OF CANCER OR IMMUNOASSAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | claimed |
| US-5344928-A | Phenothiazine compounds for cancer treatment or immunoassay using chemiluminescence | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-09-06 | — | — | US | claimed |
| EP-0510668-A2 | Phenothiazine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199833-A1 | Novel chemiluminescent compounds and their use | LANCL1, LPO, HLCS | TSHR 694/4885NPSR1 2176/4885RXFP1 1223/4885 |
| US-20060199223-A1 | storage stability; immunoassays | SHBG, SELL, XIAP | TSHR 1120/4885NPSR1 1908/4885RXFP1 3704/4885 |
| US-20060172358-A1 | Novel chemiluminescent compounds and their use | LANCL1, LPO, HLCS | TSHR 694/4885NPSR1 2176/4885RXFP1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.